文献速递免疫规划慢病防控与筛查

多样化免疫功能受损患者人群中SARS-CoV-2疫苗失败率及免疫应答预测因素

SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient population.
PubMed 文献 · Vaccine · 2025-07-12

这项前瞻性研究采集293例可能免疫功能受损患者首次接种前及第二、三剂接种后的血清,检测抗刺突蛋白IgG和中和抗体滴度以评估疫苗失败率。第二、三剂接种后6个月内基于IgG的疫苗失败率分别为22.4%和12.0%,基于中和试验分别为32.7%和13.9%。接受B细胞清除治疗者疫苗失败风险最高,而细胞毒性化疗或免疫检查点抑制剂者风险最低。

要点

  • 第二、三剂接种后6个月内基于IgG的疫苗失败率分别为22.4%和12.0%。
  • 基于中和试验的疫苗失败率分别为32.7%和13.9%。
  • 第二剂接种后6个月内12.2%样本血清学阳性但无功能性中和抗体。

核心结论

  • 在接受潜在免疫抑制治疗的患者中,接受B细胞清除治疗者COVID-19疫苗接种后疫苗失败风险高,但失败率随后续剂次显著下降。
  • 在这些人群中,仅血清学检测阳性可能并不代表具有保护性免疫应答。

研究设计与样本

  • 前瞻性研究,采集首次接种前及第二、三剂疫苗接种后的血清标本。
  • 分析293例可能免疫功能受损患者的接种后血清样本,包括血液系统恶性肿瘤10.2%、实体瘤56.0%、神经免疫性疾病27.6%和其他6.1%。

主要发现

  • 第二剂COVID-19疫苗接种后6个月内基于IgG滴度的疫苗失败率为22.4%,第三剂后为12.0%。
  • 第二剂接种后6个月内基于中和试验的疫苗失败率为32.7%,第三剂后为13.9%。
  • 第二剂COVID-19疫苗接种后6个月内12.2%的样本血清学阳性但无功能性中和抗体(结果不匹配)。
  • 疫苗失败率最高见于接受活性B细胞清除治疗的患者(主要为血液系统恶性肿瘤或神经免疫性疾病),接受细胞毒性化疗或免疫检查点抑制剂者(主要为实体瘤患者)疫苗失败风险最低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Determining individual responses to vaccination is critical for effective prevention of SARS-CoV-2 infection, particularly in populations at risk of vaccine failure. METHODS: In this prospective study, we collected serum specimens prior to the first and post-second and -third vaccinations to examine the quantity, quality, and durability of immune responses to SARS-CoV-2 vaccination in patients receiving various immune-modulating therapies. To determine rates of vaccine failure, we measured SARS-CoV-2 anti-spike protein immunoglobulin G and neutralisation titres. FINDINGS: We analysed post-vaccination serum samples from 293 potentially immunocompromised patients (10·2 % haematologic malignancies, 56·0 % solid tumours, 27·6 % neuroimmunological conditions, and 6·1 % other). Based on IgG titres, 22·4 % and 12·0 % of cases were deemed vaccine failures by serology within 6 months of the second and third COVID-19 vaccinations, respectively; these rates were 32·7 % and 13·9 %, respectively, based on neutralisation. Notably, 12·2 % of samples did not have functional neutralising antibodies despite positive serology (mismatched result) within 6 months of the second COVID-19 vaccine dose. The highest rate of vaccine failure occurred in patients receiving active B-cell depleting therapies (primarily haematological malignancies or neuroimmunological conditions); those receiving cytotoxic chemotherapy or immune checkpoint inhibitors (predominantly patients with solid tumours) were at the lowest risk for vaccine failure. INTERPRETATION: Among patients receiving potentially immunosuppressive therapies, individuals treated with B-cell depletion therapies have high risk for vaccine failure after COVID-19 vaccination, but the rate of failure declines significantly with subsequent doses. In these populations, positive serology tests alone may not signify a protective immune response. FUNDING: Supported by a grant from Regeneron Pharmaceuticals, Inc., and P54 CA260560.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Greenberg BM, Minna JD, Gerber DE, et al. SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient population. Vaccine. 2025. PMID: 40652684. doi:10.1016/j.vaccine.2025.127473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。